Y Intercept Hong Kong Ltd Takes $4.79 Million Position in Chemed Corporation $CHE

Y Intercept Hong Kong Ltd acquired a new stake in Chemed Corporation (NYSE:CHE) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,837 shares of the company’s stock, valued at approximately $4,790,000. Y Intercept Hong Kong Ltd owned approximately 0.07% of Chemed at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. HM Payson & Co. purchased a new stake in shares of Chemed in the first quarter valued at approximately $30,000. SVB Wealth LLC purchased a new stake in shares of Chemed in the first quarter valued at approximately $30,000. WPG Advisers LLC purchased a new stake in shares of Chemed in the first quarter valued at approximately $32,000. Geneos Wealth Management Inc. increased its position in shares of Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after buying an additional 76 shares in the last quarter. Finally, Zions Bancorporation National Association UT purchased a new stake in shares of Chemed in the first quarter valued at approximately $68,000. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Chemed news, Director George J. Walsh III bought 200 shares of Chemed stock in a transaction on Monday, August 4th. The shares were bought at an average price of $417.10 per share, for a total transaction of $83,420.00. Following the completion of the transaction, the director directly owned 3,523 shares of the company’s stock, valued at $1,469,443.30. This trade represents a 6.02% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Patrick P. Grace sold 150 shares of Chemed stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total value of $69,508.50. Following the completion of the sale, the director owned 3,397 shares in the company, valued at $1,574,135.83. This represents a 4.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 13,162 shares of company stock worth $5,677,511. 3.29% of the stock is currently owned by corporate insiders.

Chemed Stock Performance

NYSE CHE opened at $440.35 on Wednesday. The stock’s fifty day moving average is $448.09 and its two-hundred day moving average is $495.79. The firm has a market capitalization of $6.42 billion, a P/E ratio of 22.64, a price-to-earnings-growth ratio of 2.53 and a beta of 0.43. Chemed Corporation has a fifty-two week low of $408.42 and a fifty-two week high of $623.60.

Chemed (NYSE:CHE) last released its quarterly earnings data on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The company had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%.The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm posted $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, sell-side analysts forecast that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 11th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. This is an increase from Chemed’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend was Monday, August 11th. Chemed’s dividend payout ratio is presently 12.34%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on CHE shares. Bank of America cut their price objective on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research report on Wednesday, September 10th. Oppenheimer lowered their price target on Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research note on Thursday, July 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, October 8th. Wall Street Zen lowered Chemed from a “buy” rating to a “hold” rating in a research note on Saturday, July 5th. Finally, Jefferies Financial Group raised Chemed from a “hold” rating to a “buy” rating and lifted their price target for the stock from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Chemed presently has a consensus rating of “Moderate Buy” and a consensus target price of $578.50.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.